Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Piperaquine Dispersible Granules vs Tablets in Healthy Adults
NCT05930782Phase 1Completed
- Sponsor
- Medicines for Malaria Venture
- Start
- Aug 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of piperaquine in malaria (5 arms), sponsored by Medicines for Malaria Venture. Primary endpoints: Relative Bioavailability of Maximum Observed Plasma Concentration at Day 30, Relative Bioavailability of Area Under the Plasma Concentration-time Curve 0-72h at Day 30 and 3 more. Started Aug 2023; status: completed.
02
Drugs
piperaquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05930782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05930782.